Posted by Michael Wonder on 03 May 2018
FDA updates Trintellix (vortioxetine) label to include data showing improvement in processing speed, an important aspect of cognitive function in acute major depressive disorder
2 May 2018 - Trintellix (vortioxetine) is the first FDA-approved treatment for MDD to have data in the U.S. Prescribing Information showing a positive effect on processing speed, an aspect of cognitive function that is impaired in many patients with MDD.
Lundbeck today announced the U.S. FDA approved a supplemental new drug application for Trintellix (vortioxetine). The clinical trials section of the U.S. label now includes data from the largest replicated clinical studies on an important aspect of cognitive function in acute major depressive disorder (MDD, depression).
The FOCUS and CONNECT studies show Trintellix has a positive effect on processing speed, an important aspect of cognitive function observed in some patients with MDD.
